<DOC>
	<DOCNO>NCT02258490</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( HSCT ) establish form treatment hematological abnormality . Poor graft function , occur poor donor engraftment . A second infusion unselected donor hematopoietic stem cell ( HSC ) result improvement , potentially increase incidence graft versus host disease . Cluster differentiation 34+ ( CD34+ ) select stem cell deplete T-cells attractive alternative treatment poor graft function may associate less Graft versus Host Disease ( GVHD ) enhance count recovery . The investigator use Miltenyi CliniMACS device CD34 cell selection reagent preparation allogeneic hematopoietic progenitor cell ( HPC ) transplant patient prior stem cell transplant require stem cell `` boost '' original donor .</brief_summary>
	<brief_title>Expanded Use G-CSF Mobilized Donor CD34+ Selected Cells Allogeneic Transplantation</brief_title>
	<detailed_description>This single-arm , open label , single institution , compassionate study enroll patient marginally engraft transfusion and/or growth factor dependent allogeneic hematopoietic stem cell transplant ( HSCT ) regardless underlie disease transplant perform . Study subject receive `` booster '' infusion CD34+ cell select T-cell deplete G-CSF mobilized apheresis product original stem cell donor order improve engraftment . The `` booster '' infusion administer without prior conditioning .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Donor Donors must eligible approve hematopoietic stem cell graft accord institutional criterion ( related donor ) NMDP criterion ( volunteer unrelated donor ) Donors must ≥ 17 year old ≤ 75 year old Donors must agreeable receive GCSF CD34 cell mobilization undergo apheresis second donation peripheral blood mononuclear cell ( PBMC ) Donor must adequate peripheral venous catheter access apheresis must agree placement central catheter The following laboratory tests/evaluations perform donor register study . Additional evaluations/studies may also perform site dictate donor 's clinical situation standard practice monitoring normal donor History physical examination Automated complete blood count ( WBC , red blood cell [ RBC ] , hematocrit , hemoglobin ) differential platelet count Serum chemistry panel include electrolyte , glucose , blood urea nitrogen ( BUN ) , alanine aminotransferase ( ALT ) , creatinine , bilirubin , alkaline phosphatase , lactate dehydrogenase ( LDH ) albumin . Electrolytes include sodium , potassium , chloride , carbon dioxide , calcium magnesium . Infections disease titer FDA license test : Cytomegalovirus ( CMV ) antibody Hepatitis panel ( Hepatitis B include HBsAg , HBcAb [ immunoglobulin M { IgM } immunoglobulin G { IgG } ] ; hepatitis C antibody ) HIV 1+2 antibody Hepatitis C virus ( HCV ) antibodies Human Tlymphotropic virus ( HTLV ) I/II antibodies Rapid plasmin reagin ( RPR ) HIV1 nucleic acid amplification test ( NAT ) HCV NAT West Nile virus ( WNV ) These test obtain , report Emory , within 30 day prior collection CD34+ cell product . Recipient Only patient experience lifethreatening hematological insufficiency , follow allogeneic hematopoietic stem cell transplant enrol study Patient must age &gt; 17 Must ≥ 90 % donor cell unfractionated peripheral blood base either XY fluorescence situ hybridization ( FISH ) standard short tandem repeat ( STR ) More 60 day post allogeneic stem cell transplantation reversible etiology find allogeneic stem cell transplantation Must meet one follow criterion : Platelets &lt; 20,000/μl , absolute neutrophil count ( ANC ) &lt; 500/μl Transfusion dependent least one cell line and/or On growth factor support ( GCSF ) without adequate response 30 day The original HSCT donor must available , willing , medically able undergo GCSF mobilization apheresis procedures Patients must nonimmune mediate graft dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>CD34+ cell mobilization therapy</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>allogeneic hematopoietic stem cell</keyword>
	<keyword>G-CSF</keyword>
</DOC>